STOCK TITAN

Activist DOMA takes 7.3% Pacira (NASDAQ: PCRX) stake and targets CEO, board

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Pacira BioSciences, Inc. is the target of an activist campaign by DOMA Perpetual Capital Management and affiliates, which report beneficial ownership of 2,936,794 common shares, or 7.3% of the company. The group, led by Pedro Escudero, filed Amendment No. 3 to Schedule 13D.

Using 40,489,894 shares outstanding as of February 23, 2026, DOMA and related entities disclose various stakes, including 4.9% held by Doma Perpetual LO Equity Master Fund and 2% reported for The John Templeton Foundation. On March 11, 2026, Doma Master Fund notified Pacira it intends to nominate three directors at the 2026 annual meeting and to solicit proxies.

In a March 12, 2026 press release incorporated in the filing, DOMA called for chief executive officer Frank Lee to be replaced and urged the board to appoint an interim CEO. DOMA also stated its view that Pacira’s stock price has declined over several years while expenses and management compensation have increased, and urged the board to run a formal sale process to maximize value for shareholders.

Positive

  • None.

Negative

  • None.

Insights

DOMA discloses a 7.3% Pacira stake and launches a board and CEO challenge.

DOMA Perpetual Capital Management and affiliates report beneficial ownership of 2,936,794 Pacira shares, or 7.3% of outstanding common stock based on 40,489,894 shares as of February 23, 2026. This positions them as a meaningful shareholder with enough scale to mount an activist campaign.

The filing describes Doma Master Fund’s notice of intent to nominate three directors at the 2026 annual meeting and to solicit proxies. The group’s press release, incorporated by reference, states that it wants CEO Frank Lee replaced, an interim CEO appointed, and a formal sale process initiated to “maximize” asset value. These are the filers’ stated opinions and objectives.

If the slate gains support, Pacira’s governance, strategic direction, and leadership could shift, but outcomes depend on shareholder voting at the annual meeting and any board response. Future company disclosures around the nomination contest and any consideration of strategic alternatives will further clarify how this activist effort develops.






Pedro Escudero
3350 Virginia Street, Suite 530,
Miami, FL, 33131
(305) 549-5081

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
03/11/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D




Comment for Type of Reporting Person:
John Templeton Foundation beneficially owns Common Shares via its wholly-owned investment holding company, Reliability LLC.


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


DOMA PERPETUAL CAPITAL MANAGEMENT LLC
Signature:/s/ Pedro Escudero
Name/Title:Authorized Signatory
Date:03/12/2026
DOMA1 LLC
Signature:/s/ Pedro Escudero
Name/Title:Authorized Signatory
Date:03/12/2026
DOMA Perpetual LO Equity Master Fund LP
Signature:/s/ Pedro Escudero
Name/Title:Authorized Signatory
Date:03/12/2026
DOMA Perpetual Partners GP LLC
Signature:/s/ Pedro Escudero
Name/Title:DOMA Perpetual Partners GP LLC
Date:03/12/2026
Pedro Escudero
Signature:/s/ Pedro Escudero
Name/Title:Self
Date:03/12/2026
The John Templeton Foundation
Signature:/s/ Pedro Escudero
Name/Title:Authorized Signatory
Date:03/12/2026
DOMA2 LLC
Signature:/s/ Pedro Escudero
Name/Title:Authorized Signatory
Date:03/12/2026
Eric de Armas
Signature:/s/ Eric de Armas
Name/Title:Self
Date:03/12/2026

FAQ

What stake in Pacira BioSciences (PCRX) does DOMA report in this Schedule 13D/A?

The filing reports that Pedro Escudero and affiliated DOMA entities beneficially own 2,936,794 Pacira common shares, representing 7.3% of the outstanding stock, based on 40,489,894 shares outstanding as of February 23, 2026, as disclosed in Pacira’s Form 10-K.

What board actions is DOMA seeking at Pacira BioSciences (PCRX)?

Doma Master Fund notified Pacira on March 11, 2026 that it intends to nominate three directors—Eric de Armas, Christopher Dennis, and Oliver Benton Curtis III—for election to the board at the 2026 annual meeting and plans to solicit proxies in support of these nominees.

What leadership change at Pacira BioSciences (PCRX) does DOMA advocate?

In a March 12, 2026 press release incorporated into the filing, DOMA called for Pacira’s chief executive officer, Frank Lee, to be replaced immediately and for the board to appoint an interim CEO. This reflects DOMA’s stated view, not a decision by Pacira’s board.

How many Pacira shares are outstanding according to this Schedule 13D/A amendment?

The filing states that beneficial ownership percentages are calculated using 40,489,894 Pacira common shares outstanding as of February 23, 2026, based on information provided on the cover page of Pacira’s Form 10-K filed with the SEC on February 26, 2026.

What strategic changes does DOMA urge for Pacira BioSciences (PCRX)?

DOMA’s press release, referenced in the filing, states that it believes Pacira’s stock has declined while expenses and management pay increased and urges the board to conduct a formal sale process to maximize asset value and realize value for shareholders, reflecting DOMA’s perspective.

Which entities are included as reporting persons in this Pacira (PCRX) Schedule 13D/A?

Reporting persons include DOMA Perpetual Capital Management LLC, DOMA1 LLC, DOMA Perpetual LO Equity Master Fund LP, DOMA Perpetual Partners GP LLC, DOMA2 LLC, The John Templeton Foundation, and individuals Pedro Escudero and Eric de Armas, with relationships among them described in Item 2.
Pacira Biosciences Inc

NASDAQ:PCRX

View PCRX Stock Overview

PCRX Rankings

PCRX Latest News

PCRX Latest SEC Filings

PCRX Stock Data

924.38M
39.28M
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
BRISBANE